Literature DB >> 9712096

Elevated procalcitonin levels in active Wegener's granulomatosis.

F Moosig1, E Csernok, E Reinhold-Keller, W Schmitt, W L Gross.   

Abstract

OBJECTIVE: To compare serum levels of procalcitonin (PCT) in patients with Wegener's granulomatosis (WG) in both active and inactive disease states to determine if PCT levels are increased in active WG without infection.
METHODS: Sera were tested from 26 patients with generalized histologically proven WG, one sample taken during an active and one during an inactive disease state. PCT serum levels were measured using an immunoluminometric assay.
RESULTS: PCT levels were in the normal range (0-0.5 ng/ml) in 23 of 26 sera taken during active WG and in all 26 sera taken during inactive WG. In sera from 3 patients with highly active WG, serum PCT concentrations were markedly elevated (0.8-3.3 ng/ml). There was a slight but significant difference in PCT concentrations between sera taken during active versus inactive disease. PCT values were found to correlate slightly with other disease activity variables (erythrocyte sedimentation rate, C-reactive protein, soluble interleukin 2 receptor, antineutrophil cytoplasmic antibodies) and with the Disease Extent Index score.
CONCLUSION: PCT serum levels may be a potentially useful variable in the differential diagnosis of flares and bacterial infection in patients with WG. Interpretation of the values must be supported by laboratory and clinical findings, since PCT levels can be elevated in rare cases of highly active WG without infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9712096

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  12 in total

Review 1.  Validation of new biomarkers in systemic autoimmune diseases.

Authors:  Maria G Tektonidou; Michael M Ward
Journal:  Nat Rev Rheumatol       Date:  2011-11-01       Impact factor: 20.543

2.  Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy.

Authors:  Yizhi Xiao; Hui Luo; Bin Zhou; Xiaodan Dai; Jing Huang; Liping Duan; Yunhui You; Weiru Zhang; Hongjun Zhao; Yanli Xie; Yaou Zhou; Wangbin Ning; Tong Li; Sijia Liu; Honglin Zhu; Xiaoyun Xie; Ying Jiang; Shiyao Wu; Weijia He; Yisha Li
Journal:  Rheumatol Int       Date:  2016-11-22       Impact factor: 2.631

3.  Assessment of the correlation of commonly used laboratory tests with clinical activity, renal involvement and treatment of systemic small-vessel vasculitis with the presence of ANCA antibodies.

Authors:  Magdalena Mosakowska; Dorota Brodowska Kania; Katarzyna Szamotulska; Aleksandra Rymarz; Stanisław Niemczyk
Journal:  BMC Nephrol       Date:  2021-08-26       Impact factor: 2.388

4.  Role of procalcitonin in infectious gastroenteritis and inflammatory bowel disease.

Authors:  Kelvin Teck-Joo Thia; Edwin Shih-Yen Chan; Khoon-Lin Ling; Wai-Yoong Ng; Edward Jacob; Choon-Jin Ooi
Journal:  Dig Dis Sci       Date:  2008-04-16       Impact factor: 3.199

5.  Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes?

Authors:  I Delèvaux; M André; M Colombier; E Albuisson; F Meylheuc; R-J Bègue; J-C Piette; O Aumaître
Journal:  Ann Rheum Dis       Date:  2003-04       Impact factor: 19.103

Review 6.  Update on procalcitonin measurements.

Authors:  Michael Meisner
Journal:  Ann Lab Med       Date:  2014-06-19       Impact factor: 3.464

7.  Combining Calcitonin and Procalcitonin and Rheumatoid Arthritis-Related Biomarkers Improve Diagnostic Outcomes in Early Rheumatoid Arthritis.

Authors:  Yingwen Liu; Jing Shi; Bo Wang; Lijing Zhou; Xiaolan Zhou; Yane Du; Dandan Li; Liang Duan; Qin Hu; Weixian Chen; Pu Li
Journal:  Dis Markers       Date:  2021-05-26       Impact factor: 3.434

8.  The utility of initial procalcitonin and procalcitonin clearance for prediction of bacterial infection and outcome in critically ill patients with autoimmune diseases: a prospective observational study.

Authors:  Yan Shi; Jin-min Peng; Xiao-yun Hu; Yao Wang
Journal:  BMC Anesthesiol       Date:  2015-10-07       Impact factor: 2.217

9.  Diagnostic Value of Procalcitonin in ANCA-Associated Vasculitis (AAV) to Differentiate Between Disease Activity, Infection and Drug Hypersensitivity.

Authors:  K Herrmann; S Schinke; E Csernok; F Moosig; J U Holle
Journal:  Open Rheumatol J       Date:  2015-10-09

10.  Procalcitonin levels in patients with complete and incomplete Kawasaki disease.

Authors:  Hwa Jin Cho; Young Earl Choi; Eun Song Song; Young Kuk Cho; Jae Sook Ma
Journal:  Dis Markers       Date:  2013-10-10       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.